A Phase 1 Study of MORAb-003 in Patients With Solid Tumor.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Farletuzumab (Primary)
- Indications Solid tumours; Tumours
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 22 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Dec 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 12 Dec 2012 Planned number of patients changed from 24 to 16 as reported by ClinicalTrials.gov.